Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

NCT00838201 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00838201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00838201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
February 1, 2009
Completion date
May 3, 2012
Enrollment
384 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, carcinoma, castrate-resistant prostate cancer, prostate cancer, tumors